Lochet Pierre, Peyrière Helène, Le Moing Vincent, Blayac Jean-Pierre, Hansel Sylvie, Reynes Jacques
Service des Maladies Infectieuses et Tropicales, Hôpital Gui de Chauliac, CHU Montpellier, Montpellier, France.
Therapie. 2005 Mar-Apr;60(2):175-81. doi: 10.2515/therapie:2005022.
The objectives of our study were to assess frequency, severity and outcome of renal abnormalities, as well as to determine the risk of developing hypophosphataemia in HIV-infected patients receiving tenofovir.
An observational study was conducted in real-life conditions, during a 6-month period, in 107 HIV patients receiving tenofovir.
Mild-to-moderate hypophosphataemia (<0.77 mmol/L) occurred during follow-up, at least once in 43% of patients and at least twice in 27%. Antiretroviral therapy including ritonavir + lopinavir was significantly associated with the occurrence of hypophosphataemia (relative risk = 2.6; p = 0.03). Frequency of abnormal proteinuria was 22%.
Creatinine clearance, phosphataemia, proteinuria and glycosuria should be closely monitored in patients receiving tenofovir therapy.
